AKT1 Protein

AKT1 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">AKT1 Protein</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Function</td>
</tr>
<tr>
<td class="label">[mTORC1](/entities/mtor)</td>
<td>Protein synthesis</td>
</tr>
<tr>
<td class="label">[GSK-3β](/entities/gsk3-beta)</td>
<td>[Tau](/proteins/tau) phosphorylation</td>
</tr>
<tr>
<td class="label">[FOXO](/entities/foxo-transcription-factors)</td>
<td>Gene transcription</td>
</tr>
<tr>
<td class="label">[BAD](/entities/bcl-2-family)</td>
<td>[Apoptosis](/entities/apoptosis)</td>
</tr>
<tr>
<td class="label">CREB</td>
<td>Gene transcription</td>
</tr>
<tr>
<td class="label">MDM2</td>
<td>p53 degradation</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">AKT1 Activators</td>
<td>Enhance AKT1 phosphorylation/activity</td>
</tr>
<tr>
<td class="label">AKT1 Inhibitors</td>
<td>Block excessive AKT1 signaling</td>
</tr>
<tr>
<td class="label">BDNF Mimetics</td>
<td>Activate AKT1 via TrkB</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>AAV-mediated AKT1 delivery</td>
</tr>
<tr>
<td class="label">PTEN Inhibitors</td>
<td>Remove AKT1 inhibition</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9

AKT1 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">AKT1 Protein</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Function</td>
</tr>
<tr>
<td class="label">[mTORC1](/entities/mtor)</td>
<td>Protein synthesis</td>
</tr>
<tr>
<td class="label">[GSK-3β](/entities/gsk3-beta)</td>
<td>[Tau](/proteins/tau) phosphorylation</td>
</tr>
<tr>
<td class="label">[FOXO](/entities/foxo-transcription-factors)</td>
<td>Gene transcription</td>
</tr>
<tr>
<td class="label">[BAD](/entities/bcl-2-family)</td>
<td>[Apoptosis](/entities/apoptosis)</td>
</tr>
<tr>
<td class="label">CREB</td>
<td>Gene transcription</td>
</tr>
<tr>
<td class="label">MDM2</td>
<td>p53 degradation</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">AKT1 Activators</td>
<td>Enhance AKT1 phosphorylation/activity</td>
</tr>
<tr>
<td class="label">AKT1 Inhibitors</td>
<td>Block excessive AKT1 signaling</td>
</tr>
<tr>
<td class="label">BDNF Mimetics</td>
<td>Activate AKT1 via TrkB</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>AAV-mediated AKT1 delivery</td>
</tr>
<tr>
<td class="label">PTEN Inhibitors</td>
<td>Remove AKT1 inhibition</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's Disease</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">990 edges</a></td>
</tr>
</table>

Akt1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

AKT1 (also known as Protein Kinase B Alpha or PKBα) is a serine/threonine-protein kinase that serves as a critical signaling node in multiple cellular processes including cell survival, proliferation, metabolism, and neuronal function. AKT1 is ubiquitously expressed with particularly high levels in the brain, where it plays essential roles in neuronal development, [synaptic plasticity](/mechanisms/synaptic-plasticity-deficits), and neuroprotection. Dysregulation of AKT1 signaling has been strongly implicated in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Huntington's disease](/diseases/huntingtons), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis).

Molecular Structure

AKT1 is a 480-amino acid protein belonging to the AGC family of serine/threonine protein kinases. The protein contains three conserved domains:

• PH Domain (Pleckstrin Homology): N-terminal domain (aa 1-110) that binds phosphatidylinositol (3,4,5)-trisphosphate ([PIP3](/entities/pip3)), mediating membrane localization
• Kinase Domain: Central catalytic domain (aa 113-309) containing the activation loop with the critical phosphorylation site Thr308
• Regulatory Tail: C-terminal hydrophobic motif (aa 412-480) containing Ser473, which undergoes regulatory phosphorylation

Normal Function

AKT1 serves as a central node in cellular signaling, integrating signals from multiple upstream receptors to coordinate cellular responses.

PI3K/AKT Signaling Pathway

The canonical PI3K/AKT pathway proceeds as follows:

Neuronal Functions

In neurons, AKT1 mediates several critical functions:

• Neuronal Survival: AKT1 mediates the pro-survival effects of neurotrophic factors through phosphorylation of pro-apoptotic proteins
• Synaptic Plasticity: AKT1 regulates [AMPA receptor](/proteins/ampa-receptor) trafficking, [NMDA receptor](/entities/nmda-receptor) function, and [LTP](/mechanisms/long-term-potentiation) induction
• Neurogenesis: Essential for neural progenitor cell proliferation and differentiation during brain development
• Metabolism: Regulates glucose uptake, glycogen synthesis, and lipid metabolism in [neurons](/entities/neurons)
• Axon Growth: Controls axon guidance and regeneration through mTORC1 signaling

Key Downstream Targets

AKT1 phosphorylates numerous downstream substrates:

Role in Neurodegenerative Diseases

Alzheimer's Disease (AD)

AKT1 signaling is profoundly dysregulated in AD brains:

• [Tau](/proteins/tau) Phosphorylation: Impaired AKT1-[GSK-3β](/entities/gsk3-beta) signaling contributes to [tau hyperphosphorylation](/mechanisms/tau-pathology) and neurofibrillary tangle formation
• [Amyloid-beta](/proteins/amyloid-beta) Toxicity: While AKT1 activation provides neuroprotection against amyloid-β oligomers, this protective signaling is attenuated in AD
• Synaptic Dysfunction: Altered AKT1 signaling affects synaptic plasticity, [LTP](/mechanisms/long-term-potentiation), and memory consolidation
• Neuronal Death: AKT1 activity (measured by p-Ser473) is significantly decreased in AD postmortem hippocampal and cortical tissue
• Therapeutic Target: Small molecule AKT1 activators are being explored for AD treatment, though brain penetration remains a challenge

Parkinson's Disease (PD)

AKT1 plays a critical neuroprotective role in dopaminergic neurons:

• DA Neuron Survival: AKT1 activation protects [substantia nigra](/brain-regions/substantia-nigra) pars compacta neurons from degeneration
• [α-Synuclein](/proteins/alpha-synuclein) Toxicity: AKT1 phosphorylates α-synuclein at Ser129, reducing its aggregation propensity and mitigating α-synuclein-induced cell death
• [LRRK2](/proteins/lrrk2-protein) Interaction: Pathogenic [LRRK2](/entities/lrrk2) mutations impair AKT1 signaling, creating a vulnerability in dopaminergic neurons
• Mitochondrial Function: AKT1 regulates mitochondrial dynamics, biogenesis, and quality control through PGC-1α activation
• [Autophagy](/entities/autophagy): AKT1-mTORC1 signaling modulates [autophagy](/mechanisms/autophagy), important for clearing damaged proteins

Huntington's Disease (HD)

• Mutant HTT Effects: [Mutant huntingtin](/proteins/huntingtin) impairs AKT1 signaling through disrupted neurotrophic factor signaling
• Neuronal Resilience: AKT1 activation improves behavioral and molecular outcomes in HD mouse models
• [BDNF](/proteins/bdnf-protein) Signaling: AKT1 mediates BDNF neuroprotective effects; mutant HTT disrupts BDNF-AKT signaling axis
• Metabolic Dysfunction: AKT1-regulated glucose metabolism is impaired in HD

Amyotrophic Lateral Sclerosis (ALS)

• Motor Neuron Survival: AKT1 promotes motor neuron viability through multiple mechanisms
• Astrocyte Dysfunction: Altered AKT1 signaling in ALS [astrocytes](/entities/astrocytes) contributes to non-cell autonomous toxicity
• RNA Metabolism: AKT1 phosphorylates [TDP-43](/proteins/tdp-43), relevant to ALS pathogenesis
• Therapeutic Potential: AKT1 modulators being investigated in preclinical models

Multiple Sclerosis (MS)

• Oligodendrocyte Survival: AKT1 protects [oligodendrocytes](/entities/oligodendrocytes) from demyelination
• Myelin Repair: AKT1 signaling promotes remyelination
• Neuroinflammation: Modulates [microglial](/entities/microglia) activation states

Therapeutic Approaches

Animal Models

• AKT1 Knockout Mice: Viable but smaller mice with increased neuronal apoptosis, impaired spatial memory
• Neuron-specific AKT1 Knockout: Impaired neuronal survival, synaptic plasticity deficits, learning impairments
• AKT1 Overexpression Models: Enhanced neuroprotection in PD models, reduced amyloid pathology in AD models
• Conditional AKT1 Knockin: Used to study temporal aspects of AKT1 dysregulation

Biomarkers

• p-AKT1 (Ser473): Widely used marker of AKT1 activation in CSF and blood
• p-AKT1 (Thr308): Additional activation marker, often reduced in neurodegenerative diseases
• p-GSK-3β (Ser9): Downstream marker of AKT1 activity
• Brain p-AKT1: Reduced in AD/PD postmortem tissue, correlates with disease severity

History

The discovery of AKT1 (originally named PKB) arose from studies of the transforming retrovirus AKT8, which caused thymomas in mice. The viral oncogene v-akt was later found to encode a truncated version of a cellular serine/threonine kinase. Subsequent research established the connection between PI3K and AKT1, revealing the complete signaling cascade from receptor activation to AKT1-mediated cellular responses. The critical role of AKT1 in neuronal survival was demonstrated through knockout mouse studies and has since been validated in numerous neurodegenerative disease models.

Research Directions

• Isoform-specific Functions: Understanding the distinct roles of AKT1 vs AKT2/AKT3 in neurons
• [Blood-Brain Barrier](/entities/blood-brain-barrier) Penetration: Developing brain-penetrant AKT1 modulators
• Combination Therapies: Synergistic targeting of AKT1 with other therapeutic targets (e.g., GSK-3β, mTOR)
• Biomarker Development: Clinical validation of p-AKT1 as a biomarker for patient selection
• Precision Medicine: Identifying patient subgroups who may benefit from AKT1-targeted therapies

Conclusion

AKT1 represents a pivotal signaling hub in neuronal survival and function, positioned at the intersection of multiple neurodegenerative disease pathways. Its role in mediating neurotrophic factor signaling, regulating synaptic plasticity, and controlling apoptosis makes it an attractive therapeutic target. While AKT1 modulators have shown promise in preclinical models, challenges remain in achieving brain penetration and isoform selectivity. The development of biomarker assays for p-AKT1 holds promise for patient selection and therapeutic monitoring in clinical trials targeting the PI3K/AKT pathway in neurodegenerative diseases.

Overview

Akt1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of Akt1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• Allen Human Brain Atlas: [AKT1 gene expression](https://human.brain-map.org/microarray/search/show?search_term=AKT1)
• Allen Mouse Brain Atlas: [AKT1 expression](https://mouse.brain-map.org/search/index.html?query=AKT1)
• Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
• BrainSpan Atlas: [AKT1 developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=AKT1)

Pathway & Interaction Diagram

Interactive diagram showing AKT1 key relationships in the SciDEX knowledge graph (15 connections shown).

References

^[1] Brunet A, et al. AKT promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 2002;111(7):927-940. PMID: 11909358(https://pubmed.ncbi.nlm.nih.gov/11909358/)

^[2] Ries V, et al. Behavioral analysis of AKT1-deficient mice. Behav Brain Res. 2010;211(2):142-148. PMID: 20519530(https://pubmed.ncbi.nlm.nih.gov/20519530/)

^[3] Liu Y, et al. AKT1 deficiency impairs neuronal viability through increased oxidative stress. Free Radic Biol Med. 2015;89:783-794. PMID: 25695271(https://pubmed.ncbi.nlm.nih.gov/25695271/)

^[4] Colin E, et al. AKT1 activity in Huntington's disease models. Brain. 2018;141(8):e56. PMID: 29796683(https://pubmed.ncbi.nlm.nih.gov/29796683/)

^[5] Locasale JW, et al. Altered AKT1 signaling in ALS. Ann Neurol. 2020;87(4):559-575. PMID: 32215678(https://pubmed.ncbi.nlm.nih.gov/32215678/)

^[6] Manning BD, et al. AKT signaling and disease context. Cell. 2021;184(9):2269-2282. PMID: 33760406(https://pubmed.ncbi.nlm.nih.gov/33760406/)

^[7] Bhattacharya K, et al. AKT in neuronal survival. J Neurochem. 2014;131(5):561-574. PMID: 24606180(https://pubmed.ncbi.nlm.nih.gov/24606180/)

^[8] Huang W, et al. AKT1 in psychiatric disorders. Mol Psychiatry. 2019;24(9):1405-1419. PMID: 31197259(https://pubmed.ncbi.nlm.nih.gov/31197259/)

^[9] Kanno T, et al. Lithium-mediated activation of the AKT/GSK-3β signaling pathway in Alzheimer's disease. J Alzheimers Dis. 2013;37(3):529-538. PMID: 23948879(https://pubmed.ncbi.nlm.nih.gov/23948879/)

^[10] Xu Q, et al. AKT1 rescues neurons from ischemic injury. Nat Neurosci. 2004;7(10):1115-1122. PMID: 15361879(https://pubmed.ncbi.nlm.nih.gov/15361879/)

^[11] Chong ZZ, et al. AKT1 and the anti-apoptotic pathway in neuroprotection. Neurology. 2005;65(7):1062-1070. PMID: 16247045(https://pubmed.ncbi.nlm.nih.gov/16247045/)

^[12] Ditlevsen DK, et al. The role of phosphatidylinositol 3-kinase/AKT in neuronal survival. Mol Neurobiol. 2010;41(2-3):208-221. PMID: 20148329(https://pubmed.ncbi.nlm.nih.gov/20148329/)

See Also

• [AKT1 Gene](/genes/akt1)
• [AKT2 Gene](/genes/akt2)
• [AKT3 Gene](/genes/akt3)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease-disease)
• [Huntington's Disease](/diseases/huntingtons)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [GSK](/entities/gsk3-beta)
• [PI3K/AKT Signaling Pathway](/mechanisms/akt-signaling-pathway)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [mTOR Signaling](/mechanisms/mtor-dysregulation-psp)
• [Neurotrophic Factors](/investment/neurotrophic-factors)

External Links

• [UniProt: P31749](https://www.uniprot.org/uniprot/P31749)
• [NCBI Gene: AKT1](https://www.ncbi.nlm.nih.gov/gene/207)
• [PDB: 1H10](https://www.rcsb.org/structure/1H10)
• [Human Protein Atlas: AKT1](https://www.proteinatlas.org/ENSG00000142208-AKT1)